Hebei Changshan Biochem Pharma Cash Flow-to-Debt Ratio
Hebei Changshan Biochem Pharma cash flow-to-debt ratio. Hebei Changshan Biochem Pharma (300255) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of CN¥-30.86 Million could theoretically repay 0% of its total liabilities (CN¥3.18 Billion) in one year. Check 300255 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hebei Changshan Biochem Pharma (2008–2024)
Cash flow-to-debt ratio of Hebei Changshan Biochem Pharma from 2008 to 2024. Historical debt coverage capacity for Hebei Changshan Biochem Pharma across 17 annual periods. Check 300255 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Hebei Changshan Biochem Pharma Cash Flow-to-Debt Ratio by Year (2008–2024)
Hebei Changshan Biochem Pharma cash flow-to-debt ratio by year from 2008 to 2024. Year-by-year debt coverage analysis for Hebei Changshan Biochem Pharma. For the full cash flow conversion analysis, see Hebei Changshan Biochem Pharma operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | CN¥56.22 Million | CN¥2.99 Billion | ▲ +56.1% |
| 2023 | 0.01x | CN¥33.73 Million | CN¥2.80 Billion | ▲ +1050.4% |
| 2022 | 0.00x | CN¥3.13 Million | CN¥2.98 Billion | ▼ -22.7% |
| 2021 | 0.00x | CN¥2.87 Million | CN¥2.12 Billion | ▲ +101.3% |
| 2020 | -0.11x | CN¥-183.58 Million | CN¥1.72 Billion | ▼ -124.2% |
| 2019 | -0.05x | CN¥-58.13 Million | CN¥1.22 Billion | ▼ -121.5% |
| 2018 | 0.22x | CN¥292.81 Million | CN¥1.32 Billion | ▲ +49.4% |
| 2017 | 0.15x | CN¥162.28 Million | CN¥1.09 Billion | ▼ -27.4% |
| 2016 | 0.20x | CN¥171.96 Million | CN¥842.59 Million | ▲ +505.1% |
| 2015 | -0.05x | CN¥-38.14 Million | CN¥757.07 Million | ▲ +63.4% |
| 2014 | -0.14x | CN¥-84.97 Million | CN¥617.87 Million | ▼ -224.5% |
| 2013 | -0.04x | CN¥-15.24 Million | CN¥359.78 Million | ▲ +82.4% |
| 2012 | -0.24x | CN¥-70.62 Million | CN¥292.77 Million | ▼ -381.4% |
| 2011 | 0.09x | CN¥17.04 Million | CN¥198.78 Million | ▼ -38.1% |
| 2010 | 0.14x | CN¥29.25 Million | CN¥211.25 Million | ▼ -38.7% |
| 2009 | 0.23x | CN¥24.21 Million | CN¥107.15 Million | ▲ +175.6% |
| 2008 | -0.30x | CN¥-30.83 Million | CN¥103.16 Million | — |